Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.
Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
Type:
Grant
Filed:
July 16, 2010
Date of Patent:
April 24, 2012
Assignee:
ProteoTech, Inc.
Inventors:
Alan D Snow, Beth Nguyen, Gerardo Castillo, Virginia Sanders, Thomas Lake, Lesley Larsen, Rex T Weavers, Stephen Lorimer, David Larsen, David L Coffen, Charlotte Coffen, legal representative
Abstract: Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
August 23, 2011
Assignee:
Proteotech Inc.
Inventors:
Thomas Lake, Alan D. Snow, Gerardo Castillo, Beth Nguyen, Virginia Sanders, Qubai Hu, Judy A. Cam
Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.
Type:
Grant
Filed:
July 10, 2009
Date of Patent:
April 5, 2011
Assignee:
Proteotech, Inc.
Inventors:
Luke A. Esposito, Joel Cummings, F. Michael Hudson, Alan D. Snow
Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
Type:
Grant
Filed:
November 4, 2008
Date of Patent:
July 27, 2010
Assignee:
Proteotech, Inc.
Inventors:
Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
Abstract: A method of treating an amyloid disease in a patient or inhibiting the formation, deposition, accumulation, or persistence, of amyloid fibrils, amylin fibrils, or islet amyloid fibrils, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in type II diabetes in a mammalian subject. In the method a therapeutically effective amount of plant matter form the genus Uncaria, species Tomentosa is administered, preferably from the inner bark or root tissue of Uncaria Tomentosa.
Abstract: Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.
Type:
Grant
Filed:
January 9, 2006
Date of Patent:
June 29, 2010
Assignee:
Proteotech, Inc.
Inventors:
Alan D. Snow, Beth P. Nguyen, Thomas P. Lake, Gerardo M. Castillo, Manfred Weigele
Abstract: A screening assay for selecting macromolecules that interfere with the binding of a sulfated GAG to beta amyloid, the assay comprising affixing a sulfated GAG to a substrate, co-incubating the macromolecule and a known amount of beta amyloid with the sulfated GAG, determining the amount of beta amyloid bound to the sulfated GAG affixed to the substrate; wherein the macromolecule will be one which interferes with the binding of the sulfated GAG to beta amyloid.
Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A? peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.
Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
Type:
Grant
Filed:
March 5, 2007
Date of Patent:
October 13, 2009
Assignee:
Proteotech, Inc.
Inventors:
Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.